Cabazitaxel

Evidence Level: L5

Predicted Indications: 10

Cabazitaxel

Pharmacist Assessment Report

Cabazitaxel: taxane microtubule inhibitor → female breast carcinoma

One-Sentence Summary

Cabazitaxel is a taxane-class cytotoxic drug that stabilises microtubules. The TxGNN model predicts it may be effective for female breast carcinoma. No clinical trials are listed for this prediction, but 20 publications were compiled, including one randomised phase II neoadjuvant study (GENEVIEVE) and its long-term follow-up. Most of the other publications are preclinical or review articles.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	female breast carcinoma
TxGNN Prediction Score	0.9992
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Based on the published literature, cabazitaxel is a taxane that stabilises microtubules and blocks cell division, the same class as paclitaxel and docetaxel, which are established in breast cancer treatment.

Cabazitaxel has a low affinity for P-glycoprotein, and studies in resistant cell models show it is less cross-resistant than paclitaxel and docetaxel. This suggests possible activity in taxane-resistant breast tumours.

Human data in breast cancer come from the GENEVIEVE randomised phase II study, which compared neoadjuvant cabazitaxel with weekly paclitaxel in HER2-negative disease (triple-negative or luminal B), and from a phase I/II study of cabazitaxel plus capecitabine in metastatic breast cancer after anthracycline and taxane treatment. The remaining publications are mostly preclinical nanoformulation work.

Clinical Trial Evidence

Currently no related clinical trials registered. The human studies identified are reported in the literature below.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28768217	2017	Randomised phase II	Eur J Cancer	GENEVIEVE: cabazitaxel vs weekly paclitaxel as neoadjuvant treatment in operable triple-negative or luminal B/HER2-negative breast cancer, with pathological complete response as the endpoint
38663168	2024	Randomised phase II (long-term follow-up)	ESMO Open	Long-term outcomes of GENEVIEVE; the earlier report had shown differences in pCR rates
21339064	2011	Phase I/II	Eur J Cancer	Cabazitaxel plus capecitabine in metastatic breast cancer after anthracycline and taxane treatment; assessed maximum tolerated dose, safety and activity
25416788	2015	Preclinical/Review	Mol Cancer Ther	Resistance mechanisms; cabazitaxel was less cross-resistant than paclitaxel and docetaxel in resistant models, including MCF-7 breast cancer variants
33753567	2021	Preclinical	J Immunother Cancer	Cabazitaxel’s effect on macrophages improves CD47-targeted immunotherapy in triple-negative breast cancer
30529259	2019	Preclinical	J Control Release	Cabazitaxel-loaded nanoparticles gave complete remission in 6 of 8 tumours in a patient-derived breast cancer xenograft
38562610	2024	Preclinical	Int J Nanomedicine	Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticle variants, building on a triple-negative breast cancer xenograft model
28504249	2017	Preclinical	Acta Pharmacol Sin	Cabazitaxel-loaded polymeric micelles against breast cancer metastasis
30521787	2019	Preclinical	Chem Phys Lipids	Cabazitaxel and thymoquinone co-loaded lipospheres for breast cancer
33360926	2021	Preclinical	Colloids Surf B	Cabazitaxel-loaded nanostructured lipid carriers tested in breast cancer cell lines

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 4376H	Cabazitaxel Juno	Concentrated injection 60 mg in 1.5 mL, with diluent	Not recorded in the local data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (taxane, microtubule inhibitor)
Myelosuppression Risk	High (neutropenia is a leading toxicity of taxanes)
Emetogenicity Classification	Low to moderate
Monitoring Items	Full blood count with differential, liver function, renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Please also refer to the Product Information (PI) warnings and precautions.

Safety Considerations

Drug Interactions: The data compiled for this report list 100 interactions. Examples include:
- Major: deferiprone, samarium (153Sm) lexidronam
- Moderate: aprepitant, clarithromycin, clotrimazole, metronidazole, miconazole, rosuvastatin, simvastatin, ticagrelor, cobicistat, deferasirox

For other safety information, including warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cabazitaxel belongs to a drug class already established in breast cancer, and a randomised phase II study (GENEVIEVE) directly studied it in breast cancer. However, no registered trials were compiled, the evidence is limited to one phase II study with a phase I/II study, and cabazitaxel carries significant myelosuppression risk.

To proceed, the following is needed:

Review of the full GENEVIEVE results (efficacy against the paclitaxel comparator) to judge clinical benefit
Confirmation of the mechanism of action data
Review of the TGA Product Information for warnings and contraindications
A haematological and toxicity monitoring plan appropriate for breast cancer patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.